X-ray Crystallographic Studies of a Series of Penicillin-Derived Asymmetric Inhibitors of HIV-1 Protease

作者: Harren Jhoti , Onkar M. P. Singh , Malcolm P. Weir , Robert Cooke , Peter Murray-Rust

DOI: 10.1021/BI00194A005

关键词:

摘要: In the development of a treatment for AIDS, HIV-1 protease has been identified as good target enzyme inhibitor design. We previously reported series dimeric penicillin-derived C2-symmetric inhibitors [Humber, D., et al. (1993) J. Med. Chem. 36, 3120-3128]. an attempt to reduce size and optimize binding these inhibitors, molecular modeling studies led novel monomeric protease. The modes have characterized by X-ray crystallographic NMR studies. Crystal structures complexed three (GR123976, GR126045, GR137615) from this identify details interactions. GR123976 (IC50 = 2.3 microM) exhibits hydrophobic contacts but few electrostatic A strategy structure-based design chemical synthesis elaboration interactions with protein. Crystallographic analysis GR126045 GR137615 catalytic aspartates protein pockets. crystal complexes confirm presence major modeled in order potency reveal recognition nonpeptidic inhibitors.

参考文章(32)
J.T. Gerig, Fluorine nuclear magnetic resonance of fluorinated ligands. Methods in Enzymology. ,vol. 177, pp. 3- 23 ,(1989) , 10.1016/0076-6879(89)77003-8
R.A. Poorman, A.G. Tomasselli, R.L. Heinrikson, F.J. Kézdy, A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. Journal of Biological Chemistry. ,vol. 266, pp. 14554- 14561 ,(1991) , 10.1016/S0021-9258(18)98722-3
E.E. Rutenber, E.B. Fauman, R.J. Keenan, R.M. Stroud, Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. Journal of Biological Chemistry. ,vol. 268, pp. 15343- 15346 ,(1997) , 10.2210/PDB2AID/PDB
N. E. Kohl, E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, I. S. Sigal, Active human immunodeficiency virus protease is required for viral infectivity. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 4686- 4690 ,(1988) , 10.1073/PNAS.85.13.4686
A. T. BRUNGER, J. KURIYAN, M. KARPLUS, Crystallographic R Factor Refinement by Molecular Dynamics Science. ,vol. 235, pp. 458- 460 ,(1987) , 10.1126/SCIENCE.235.4787.458
Onkar M.P Singh, Dev S Baines, Richard M Hall, Norman M Gray, Malcolm P Weir, Large scale expression and purification of recombinant HIV-1 proteinase from Escherichia coli Journal of Biotechnology. ,vol. 21, pp. 127- 136 ,(1991) , 10.1016/0168-1656(91)90265-W
Dale J. Kempf, Daniel W. Norbeck, LynnMarie Codacovi, Xiu Chun Wang, William E. Kohlbrenner, Norman E. Wideburg, Deborah A. Paul, Mark F. Knigge, Sudthida Vasavanonda, Structure-based, C2 symmetric inhibitors of HIV protease. Journal of Medicinal Chemistry. ,vol. 33, pp. 2687- 2689 ,(1990) , 10.1021/JM00172A002
Risto Lapatto, Tom Blundell, Andrew Hemmings, John Overington, Andrew Wilderspin, Stephen Wood, James R. Merson, Peter J. Whittle, Dennis E. Danley, Kieran F. Geoghegan, Steven J. Hawrylik, S. Edward Lee, Kathryn G. Scheld, Peter M. Hobart, X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes Nature. ,vol. 342, pp. 299- 302 ,(1989) , 10.1038/342299A0
Joseph P. Vacca, J. P. Guare, S. J. DeSolms, W. M. Sanders, E. A. Giuliani, S. D. Young, P. L. Darke, I. S. Sigal, W. A. Schleif, L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. Journal of Medicinal Chemistry. ,vol. 34, pp. 1225- 1228 ,(1991) , 10.1021/JM00107A050